A study in Nature sheds new light on DNA repair in early human embryos, with implications for future gene correction
Peer-Reviewed Publication
Updates every hour. Last Updated: 28-Oct-2026 03:17 ET (28-Oct-2026 07:17 GMT/UTC)
Treating inherited diseases is one of the greatest challenges in modern medicine. In the future, targeted gene corrections at the earliest stages of embryonic development could help prevent certain inherited diseases from developing and being passed on to future generations. However, the safety of such approaches depends on how human embryos repair the DNA damage caused during gene editing and on the limitations of available technologies. These questions are addressed in a study published in the journal Nature, led by first author Štěpán Jeřábek, who is affiliated with both Columbia University and IOCB Prague. The research also involved two other IOCB Prague scientists, Iva Pichová and Michal Doležal.
Researchers at VCU Massey Comprehensive Cancer Center were recently awarded a $2.5 million R01 grant from the National Cancer Institute. The five-year grant will allow Massey to evaluate the efficacy of TROP2 targeted antibody-drug conjugates (ADCs) to further enhance therapeutic benefits in both breast and pancreatic cancer care.
Massey researchers, led by principal investigator Chuck Harrell, Ph.D., member of the Cancer Biology research program at Massey and professor in the Department of Pathology at the VCU School of Medicine, will look to define what enables responses and resistance to ADCs in order to identify predictive biomarkers and establish therapeutic strategies to optimize TROP2-targeted ADC efficacy in both triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC).
Researchers at King’s College London have developed a new mathematical framework to test whether AI systems that appear to explain their decisions are genuinely transparent.